ADPT:NYE-Adeptus Health Inc. (USD)

EQUITY | Biotechnology | New York Stock Exchange

Last Closing

USD 9.52

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

1.76M

Analyst Target

USD 51.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Adeptus Health Inc owns and operates First Choice Emergency Rooms, the network of independent freestanding emergency rooms in the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.38 (+0.76%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

+0.53 (+0.11%)

USD 65.38B
ARGX argenx NV ADR

+11.35 (+1.98%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+1.53 (+0.50%)

USD 32.75B
ONC BeiGene, Ltd.

+0.35 (+0.14%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.38 (+1.16%)

USD 18.35B
SMMT Summit Therapeutics PLC

-0.49 (-2.69%)

USD 13.53B
INSM Insmed Inc

+1.95 (+2.80%)

USD 11.84B
INCY Incyte Corporation

+0.25 (+0.38%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-1.02 (-1.76%)

USD 11.29B

ETFs Containing ADPT

ARCG:LSE ARK Genomic Revolution UC.. 4.59 % 0.00 %

+7.25 (+3.06%)

USD 8.76M
ARKG:LSE ARK Genomic Revolution UC.. 4.59 % 0.00 %

+0.12 (+3.06%)

USD 8.76M
WELP:LSE HAN-GINS Indxx Healthcare.. 1.24 % 0.00 %

+3.78 (+3.06%)

N/A
FYC First Trust Small Cap Gro.. 0.73 % 0.70 %

+0.29 (+3.06%)

USD 0.44B
FYX First Trust Small Cap Cor.. 0.39 % 0.63 %

-0.28 (3.06%)

USD 0.80B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

+0.72 (+3.06%)

USD 0.89B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

+0.10 (+3.06%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 58.80% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.80% 94% A 94% A
Trailing 12 Months  
Capital Gain 175.94% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 175.94% 97% N/A 97% N/A
Trailing 5 Years  
Capital Gain -75.63% 49% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -75.63% 49% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -23.66% 22% F 12% F
Dividend Return -23.66% 22% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 61.51% 54% F 29% F
Risk Adjusted Return -38.47% 30% F 20% F
Market Capitalization 0.21B 85% B 76% C+

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.90 N/A N/A
Price/Book Ratio 7.22 22% 17%
Price / Cash Flow Ratio -14.44 89% 88%
Price/Free Cash Flow Ratio -1.00 52% 72%
Management Effectiveness  
Return on Equity -61.03% 60% 28%
Return on Invested Capital -63.61% 43% 17%
Return on Assets -15.05% 82% 29%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector